位于微脈管系統(tǒng)的內(nèi)皮細(xì)胞在炎癥發(fā)生過(guò)程中扮演了“門(mén)衛(wèi)”的角色,它可以吸收循環(huán)至組織和炎癥病灶的炎癥因子。研究表明,人食道微血管內(nèi)皮細(xì)胞對(duì)脂多糖、細(xì)胞素和pH暴露表現(xiàn)出很強(qiáng)的炎癥免疫反應(yīng),因此該細(xì)胞對(duì)食道炎癥起到了關(guān)鍵的調(diào)節(jié)作用。當(dāng)暴露于酸性pH中時(shí),該細(xì)胞表達(dá)特定的蛋白,如VCAM-1,但不表達(dá)其它蛋白,如ICAM-1。這種表達(dá)方式在胃食管反流疾病引發(fā)的細(xì)胞反應(yīng)中起到了一定的作用。
Sciencell研究實(shí)驗(yàn)室的人食道微血管內(nèi)皮細(xì)胞是從人食道組織中分離得到的,一代凍存,冰凍運(yùn)輸。每管細(xì)胞密度超過(guò)5×10^5 ml。該細(xì)胞可通過(guò)VWF/Factor VIII 及 CD31 (PECAM)特異性抗體的的免疫熒光鑒定和DiI-Ac-LDL的提取鑒定。該細(xì)胞不含HIV-1、HBV、HCV、支原體、細(xì)菌、酵母菌和真菌。如采用ScienCell 實(shí)驗(yàn)室特制的培養(yǎng)基,可保證此細(xì)胞15倍增值。
推薦培養(yǎng)基:內(nèi)皮細(xì)胞培養(yǎng)基 (ECM, Cat. #1001)
貨號(hào)
|
2700
|
產(chǎn)地
|
美國(guó)
|
縮寫(xiě)
|
HEMEC
|
規(guī)格
|
5 x 10^5 /1ml
|
用途
|
科研
|
儲(chǔ)存
|
液氮
|
運(yùn)輸
|
干冰
|
關(guān)鍵字
|
人食道微血管內(nèi)皮細(xì)胞 HEMEC 人食道微血管內(nèi)皮細(xì)胞 HEMEC 人食道微血管內(nèi)皮細(xì)胞 HEMEC 人食道微血管內(nèi)皮細(xì)胞 HEMEC 人食道微血管內(nèi)皮細(xì)胞 HEMEC 人食道微血管內(nèi)皮細(xì)胞 HEMEC 人食道微血管內(nèi)皮細(xì)胞 HEMEC 人食道微血管內(nèi)皮細(xì)胞 HEMEC
|
公司簡(jiǎn)介
|
合肥星肽生物科技有限公司作為專(zhuān)業(yè)的ScienCell中國(guó)代理商,專(zhuān)業(yè)經(jīng)營(yíng)實(shí)驗(yàn)室科研用原代細(xì)胞、原代細(xì)胞專(zhuān)用培養(yǎng)基、原代細(xì)胞無(wú)血清培養(yǎng)基、干細(xì)胞、干細(xì)胞培養(yǎng)基、干細(xì)胞無(wú)血清培養(yǎng)基的研究和開(kāi)發(fā)。合肥星肽生物科技有限公司始終致力于為客戶提供可靠的研究材料以及方便快捷的服務(wù),對(duì)購(gòu)買(mǎi)項(xiàng)目的前期資料提供,中期合同保證,后期貨物跟蹤到*終售后的確保項(xiàng)目準(zhǔn)確到位,都有相關(guān)專(zhuān)業(yè)人士進(jìn)行維護(hù),確保您在合肥合肥星肽生物科技有限公司公司獲得*上等服務(wù)!
|
聯(lián)系方式
|
何經(jīng)理,合肥星肽生物科技有限公司,Tel:0551-63802898 400-8702-898,
E-mail:info@qingbio.com http://www.huangyuansheng.cn QQ:514713116
|
1.) He Y, Wang Y, Li P, Zhu S, Wang J, Zhang S. (2011) "Identification of GPX3 epigenetically silenced by CpG methylation in human esophageal squamous cell carcinoma."Dig Dis Sci. 56: 681-8.
2.) Ito T, Sato F, Kan T, Cheng Y, David S, Agarwal R, Paun BC, Jin Z, Olaru AV, Hamilton JP, Selaru FM, Yang J, Matsumura N, Shimizu K, Abraham JM, Shimada Y, Mori Y, Meltzer SJ. (2011) "Polo-like kinase 1 regulates cell proliferation and is targeted by miR-593* in esophageal cancer." Int J Cancer. 129: 2134-46.
3.) Tsuchiya S, Fujiwara T, Sato F, Shimada Y, Tanaka E, Sakai Y, Shimizu K, Tsujimoto G. (2011) "MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1)." J Biol Chem. 286: 420-8.
4.) Qazi A, Pal J, Maitah M, Fulciniti M, Pelluru D, Nanjappa P, Lee S, Batchu RB, Prasad M, Bryant CS, Rajput S, Gryaznov S, Beer DG, Weaver DW, Munshi NC, Goyal RK, Shammas MA. (2010) "Anticancer activity of a broccoli derivative, sulforaphane, in barrett adenocarcinoma: potential use in chemoprevention and as adjuvant in chemotherapy." Transl Oncol. 3: 389-99.
5.) Rafiee P, Nelson VM, Manley S, Wellner M, Floer M, Binion DG, Shaker R. (2009) "Effect of curcumin on acidic pH-induced expression of IL-6 and IL-8 in human esophageal epithelial cells (HET-1A): role of PKC, MAPKs, and NF-kappaB." Am J Physiol Gastrointest Liver Physiol. 296: G388-98.
6.) Alvarez H, Rojas PL, Yong KT, Ding H, Xu G, Prasad PN, Wang J, Canto M, Eshleman JR, Montgomery EA, Maitra A. (2008) "Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy." Nanomedicine. 4: 295-301.
7.) Ito T, Shimada Y, Kan T, David S, Cheng Y, Mori Y, Agarwal R, Paun B, Jin Z, Olaru A, Hamilton JP, Yang J, Abraham JM, Meltzer SJ, Sato F. (2008) "Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma." Cancer Res. 68: 3214-24.
8.) Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG, Gryaznov S, Weaver DW, Goyal RK. (2008) "Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo." Clin Cancer Res. 14: 4971-80.